Matissek KJ - Search Results

1

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW. Matissek KJ, et al. Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14. Cancer Discov. 2018. PMID: 29242214

2

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.

Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW. Koh SB, et al. Among authors: matissek kj. Clin Cancer Res. 2021 Sep 1;27(17):4883-4897. doi: 10.1158/1078-0432.CCR-21-0714. Epub 2021 Jun 24. Clin Cancer Res. 2021. PMID: 34168046 Free PMC article.

3

Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.

Okal A, Matissek KJ, Matissek SJ, Price R, Salama ME, Janát-Amsbury MM, Lim CS. Okal A, et al. Among authors: matissek kj. Gene Ther. 2014 Oct;21(10):903-12. doi: 10.1038/gt.2014.70. Epub 2014 Jul 31. Gene Ther. 2014. PMID: 25077773 Free PMC article.

4

Direct induction of apoptosis using an optimal mitochondrially targeted p53.

Mossalam M, Matissek KJ, Okal A, Constance JE, Lim CS. Mossalam M, et al. Among authors: matissek kj. Mol Pharm. 2012 May 7;9(5):1449-58. doi: 10.1021/mp3000259. Epub 2012 Mar 28. Mol Pharm. 2012. PMID: 22380534 Free PMC article.

5

A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.

Okal A, Mossalam M, Matissek KJ, Dixon AS, Moos PJ, Lim CS. Okal A, et al. Among authors: matissek kj. Mol Pharm. 2013 Oct 7;10(10):3922-33. doi: 10.1021/mp400379c. Epub 2013 Sep 9. Mol Pharm. 2013. PMID: 23964676

6

The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.

Matissek KJ, Mossalam M, Okal A, Lim CS. Matissek KJ, et al. Mol Pharm. 2013 Oct 7;10(10):3592-602. doi: 10.1021/mp400380s. Epub 2013 Sep 6. Mol Pharm. 2013. PMID: 23968395 Free PMC article.

7

Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax.

Matissek KJ, Okal A, Mossalam M, Lim CS. Matissek KJ, et al. Pharm Res. 2014 Sep;31(9):2503-15. doi: 10.1007/s11095-014-1346-y. Epub 2014 Mar 15. Pharm Res. 2014. PMID: 24633417 Free PMC article.

8

Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.

Okal A, Cornillie S, Matissek SJ, Matissek KJ, Cheatham TE 3rd, Lim CS. Okal A, et al. Among authors: matissek kj. Mol Pharm. 2014 Jul 7;11(7):2442-52. doi: 10.1021/mp500202p. Epub 2014 May 29. Mol Pharm. 2014. PMID: 24836513 Free PMC article.

9

Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.

Constance JE, Woessner DW, Matissek KJ, Mossalam M, Lim CS. Constance JE, et al. Among authors: matissek kj. Mol Pharm. 2012 Nov 5;9(11):3318-29. doi: 10.1021/mp3003539. Epub 2012 Oct 12. Mol Pharm. 2012. PMID: 22957899 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters